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 It is an exciting time for big data efforts in radiation oncology.  The use of big data to 22 
help aid both outcomes and decision making research is becoming a reality.  However, there 23 
are true challenges that exist in the space of gathering and utilizing performance and outcomes 24 
data.  Here, we summarize the current state of big data in radiation oncology with respect to 25 
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Introduction 28 
The promise and potential of “big data” in radiation oncology cannot be overstated.  29 
There is tremendous excitement regarding the ability to learn about the efficacy of treatment, 30 
discover new interactions, and overall being able to offer our patients improved and tailored 31 
treatments based on the experience of many. There is also the hope of shared decision making 32 
between providers and patients using informed tradeoffs between cancer control and side 33 
effects. However, genuine challenges are to be faced before this can become a reality and to 34 
meet those challenges, one must first examine the nature of this “big data.” There is a tendency 35 
to use the term “data mining” when thinking about informatics, when in fact, data farming is a 36 
more accurate term, reflecting the reality that the entire process, from planting the seeds of 37 
data in organized rows, watering and tending the growth of data, then harvesting it, is critical to 38 
understand and plan for (1). 39 
Our ability to provide patients with answers about their best course of treatment relies 40 
on our a priori knowledge of how patients with similar disease, demographics, preference, and 41 
clinical characteristics were treated, and how they responded to treatment including both 42 
tumor control and treatment-induced toxicities. This data must be captured in a useable way so 43 
that it can be extracted and analyzed, with user-friendly predictive models created so that 44 
treatment can be customized for each patient.  45 
In radiation oncology, there are two critical general issues, which must be addressed: 1.) 46 
Since radiation oncology data is different than medical/surgical oncology data, data platforms 47 
which have been designed with this in mind (many of which already exist) must be utilized. 2.) 48 
Existing standards where possible should be utilized to meet the big data needs of the multiple 49 
stakeholders (current and future patients, physicians, registries, insurance companies, the 50 
informatics community and many other groups) in radiation oncology in order to avoid 51 
duplication of work. We herein summarize the clinical aspects of big data collection in radiation 52 
oncology, and highlight the challenges and future work needed so that we can realize the 53 
potential of big data. 54 
 55 
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An essential point that must be embraced for radiation oncology big data to reach its 57 
potential is, as mentioned under 1.) above, that its format and nature is inherently different 58 
from other disciplines. Fortunately, radiation oncology has recognized this leading to a number 59 
of existing specialized data structures in its arsenal, including DICOM-RT structure and dose 60 
files. Archiving treatment images, structures and doses in DICOM format is a relatively easy first 61 
step toward ensuring that radiation oncology treatment data is captured. It also provides a 62 
great step toward future quality assurance of that data. However, some features of treatment 63 
are not captured in DICOM format, including, for example, motion management and use of 64 
bolus (if not included in the simulation).  Recreating delivered dose requires the integration of 65 
additional information (e.g. CBCT, log files from the treatment machine) in addition to the 66 
treatment plan.  67 
Standardizing nomenclature and definitions are crucial to our efforts to believe and 68 
understand aggregated data (2). There is a recognized, but currently unmet need in radiation 69 
oncology to standardize naming and delineation procedures of normal structures as well as 70 
targets. Standardization includes not only naming structures, but consistency of anatomic 71 
borders and instructions on the extent of normal organs to be contoured.  For example, naming 72 
every esophagus “esophagus” rather than “eso” or “esoph” and contouring it from the cricoid 73 
to the stomach is imperative if we hope to better understand dose-volume response- 74 
relationships. If every “esophagus” in a big data set must go through independent quality 75 
assurance, then the effort will not get very far. This is where planting the seeds correctly in the 76 
first place pays off. Even with the best intentions, the complete OAR delineation can be 77 
compromised by a treatment planning scan of limited extent, so standard nomenclature, as 78 
suggested in TG263, of partial structures is recommended for clarity (2). Another often 79 
overlooked element in radiation oncology big data is encoding of spatial information, especially 80 
with recurrence. It is essential to know the spatial location of recurrence and its relationship to 81 
the delivered dose, not just planned dose. Further, understanding why a marginal recurrence 82 
occurred (e.g. variable patient positioning, inadequate GTV/IGTV delineation, poor image 83 
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process. These are examples of data rarely available outside a research study, but essential to 85 
determining tumor dose-response relationships. 86 
 87 
Use case examples  88 
 Radiation oncology has a number of early adopters of the big data paradigm that can 89 
help guide the field into best practices for successful capture of patient outcomes data.  One 90 
well-known example is the euroCAT infrastructure (3).   Below are several other examples that 91 
were presented or discussed as part of a breakout session at the 2017 Practical Big Data 92 
Workshop.  In each example, a successful workflow has been implemented to capture 93 
outcomes and performance data.  The benefits and limitations of each use case are given 94 
below.  It should be noted that this is a list of examples and not an exhaustive list of all of the 95 
excellent big data initiatives that are ongoing in the radiotherapy community.  Table 1 attempts 96 
to summarized the use cases presented here for quick reference. 97 
 98 
M-ROAR – University of Michigan 99 
The University of Michigan has developed the Michigan Radiation Oncology Analytics 100 
Resource (M-ROAR) to aid in practice patterns and outcomes analyses in Radiation Oncology.   101 
This effort involved a multi-faceted strategy of requiring entry of critical elements as discrete 102 
data, building a database platform, which pulls data from the oncology information systems 103 
(OIS) and electronic health records (HER), and creating a self-service interface. On the data-104 
entry size, everyone in the clinic made a commitment to entering tumor staging, diagnosis 105 
code, pain scores, patient reported outcomes, and Common Terminology Criteria for Adverse 106 
Events (CTCAE) scores so that this data would be available for future analysis. Also, structure 107 
nomenclature was standardized. The MS SQL database aggregates data for >17,000 patients 108 
treated in the department since 2002, including information from both the radiation oncology 109 
and hospital information systems. The self-service interface allows users to easily create and 110 
optimize reports for cohort discovery in minutes rather than waiting to get to the top of a 111 
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With implementation of this strategy, the M-ROAR database can be used to answer 113 
innumerable clinical questions, such as what factors predict patient risk of hospitalizations, 114 
decline in patient function, and treatment-related complications, so that patient treatment 115 
protocols can be adjusted in advance. As an example, for head and neck cancer, the association 116 
between radiation dose and toxicity can be stratified based on HPV status. Information to 117 
optimize clinical operations can also be gathered, such as: How long does a certain treatment 118 
plan take to deliver vs. another one so that therapy time slots can be scheduled properly, and  119 
What patients are at risk for dehydration so that nutrition consults can be requested or 120 
outpatient hydration appointments scheduled in advance?  These are only a few examples of 121 
practice-changing queries, which are currently possible. This database is primarily to inform and 122 
guide quality improvement, with IRB approval needed when used for research.   123 
Challenges remaining in M-ROAR are consistent and standardized assessment of 124 
physician and patient-reported toxicities, as well as recurrence scoring. 125 
 126 
MD Anderson 127 
A vision of optimizing electronic health record (HER) utilization is currently being investigated at 128 
MD Anderson Cancer Center in a multiphase process. Initiated within the Radiation Oncology 129 
department, a thorough evaluation of user performance and available toolsets within EPIC was 130 
performed in order to determine suboptimal practices that were limiting efficiency within the 131 
clinic workflow. A general consensus of a need for standardized documentation and consistent 132 
nomenclature for the purposes of improving quality and safety measures, accurate staging and 133 
billing, and decreasing duplication of data entry led to the development of over 40 specialty-134 
specific templates for note generation.  These templates “pull in” discrete data elements 135 
entered into EPIC by a single person (such as a nurse, midlevel, or primary referral service) so 136 
that the need for dictation/manual data entry by other providers generating notes is 137 
minimized. The patient’s existing medical conditions, cancer stage, performance status, 138 
symptoms/ROS, laboratory values, and radiologic imaging information are all structured fields 139 
which are now automatically populated into specific locations within each template. 140 
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customizable text that can also be retrieved at a later date as structured data. Smartlists have 142 
therefore been used to define specialty-specific treatment options, protocol descriptions, and 143 
structured CTCAE grading systems. Another advantage of EPIC is the ability for patient-related 144 
outcome (PRO) forms to be sent to the patient electronically.  When patients fill out these 145 
forms, the results are then sent back and saved in EPIC as discrete data, which is then 146 
incorporated into templates and allows for more rapid documentation. 147 
 148 
Overall, these templates offer additional advantages including increased patient screening for 149 
protocol enrollment and user-friendly, electronic functionality for various research endeavors. 150 
By having the variables listed above as structured, extractable data, every aspect of clinical 151 
research becomes optimized. Patients can be quickly assessed and evaluated for protocol 152 
eligibility, and once the patient is undergoing treatment under protocol, the collection and 153 
reporting of clinical response and toxicity become more automated. Protocol-specific templates 154 
have been created in order to ensure that all required data collection per individual protocol is 155 
recorded in a uniform manner. Since completing phases I and II of template creation and 156 
implementation within the Radiation Oncology department, there have been ongoing efforts to 157 
expand standardized EHR documentation methods within other departments, beginning with 158 
GI Medical Oncology and GI Surgery. So far, these services are adapting the templates to 159 
maintain a similar data entry structure while tailoring sections such as the impression and plan 160 
to suit their documentation needs. Our ultimate goal is to have the entire institution adopt the 161 
use of standardized templates and structured data entry to 1) improve the efficiency of 162 
documentation for providers and decrease the risk of provider burn-out, 2) improve patient 163 
coordination within a multidisciplinary clinic setting, and 3) create an institution-wide system of 164 
patient data collection for research purposes and assessment of clinical outcomes. 165 
 166 
Pediatric Proton Registry Consortium 167 
The Pediatric Proton Consortium Registry (PPCR) was established in 2012 to expedite 168 
proton outcomes research in children and to better define the role of proton radiotherapy in 169 
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in the PPCR across 13 participating pediatric proton centers. The PPCR is a consented registry 171 
built upon the NIH supported free web-based data collection/repository platform, REDCap and 172 
is currently open to any U.S. proton center that would like to participate. The PPCR collects 173 
information on demographics, diagnosis and staging, baseline health status, chemotherapy and 174 
surgery, radiation details, diagnostic imaging, and follow-up (5). Radiation plans are centrally 175 
archived in the universal DICOM-RT format.   Due to funding issues and required manual effort, 176 
there is limited participation and variable data entry.  Thus, there is an urgent need to improve 177 
efficiency of data collection through automation. 178 
The major challenges within the PPCR also present opportunities. Given that there are a 179 
limited number of OIS and EHR platforms, there exists an opportunity to leverage the data 180 
already contained within these platforms if appropriate programming bridges can be 181 
constructed. An upfront investment of time and resources from technical personnel is needed 182 
and standard interface should be created with standard basic information mapped from stable 183 
locations in each OIS to minimize the need for additional customization at multiple sites. 184 
Another opportunity exists with the general EHR. Given the critical mass of EPIC users in 185 
the PPCR, we may be able to leverage collaboration to streamline data input and extraction. A 186 
start could be the sharing and use of electronic templates and automation of population of 187 
certain (standardized) fields in the database. It is key that templates must be efficient and user-188 
friendly with minimal free text so that clinicians will use them routinely and must be convinced 189 
in the overall mission or be given timesaving in another area to counter-balance the extra work 190 
of discrete data input. 191 
The final component of PPCR is aggregation of plan information, which is eventually 192 
used to help make the link between radiation dose and treatment outcomes. To facilitate this, a 193 
partnership has been put in place with MiM Software (MiM Software Inc, Cleveland, OH) to 194 
allow web-based archival for each participating institution. The partnership has led to the 195 
development of a faster anonymization procedure and a script for automated nomenclature 196 
standardization using TG263 (2).  197 
In summary, the PPCR is an established and successful registry that has met some 198 
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electronic efficiencies that will help PPCR and other Radiation Oncology-related Big Data 200 
efforts. Sufficient funding is critical to success of data collection. Mild funding pressure can spur 201 
technological advances that can improve efficiencies, but these also need an upfront 202 
investment in order to achieve them. Given the relatively few electronic radiation charts and 203 
the few EHRs, we are better poised than ever to start to realize the goal of automation in data 204 
entry.   205 
 206 
Oncospace 207 
The Oncospace program at Johns Hopkins began with the design of a relational 208 
analytical database that housed the treatment planning data in a form for fast query. The 209 
database schema includes the full 3D dose for multiple radiation therapy sessions as well as the 210 
3D anatomy including relevant structures (5). The system also houses features of the dose such 211 
as the dose-volume histograms (DVHs) and shape relationships in the overlap volume 212 
histograms (OVHs) (6). In the earlier work, the database was used for the development of 213 
shape-based automated treatment planning where one could rapidly query the OVHs to 214 
determine all prior treatments with critical organ that were “harder” to plan and use it to 215 
predict the best achievable dose metric from DVHs (7-10). This method is in use today for both 216 
plan quality evaluation and automated planning. 217 
 For outcomes, the Oncospace philosophy was that prospective structured data 218 
collection should be integrated with the clinical workflow. Since 2007, a website enabling tablet 219 
devices to be used in the clinic for data capture is available (11). Critical to the adoption is the 220 
ability to generate clinical notes from the collected structured data and additional patient-221 
related information queried from the OIS. Using the same technology, electronic patient-222 
reported outcomes have been successfully captured for more than 8 years. Currently, there are 223 
>5000 patients (prostate, head and neck, thoracic, breast and pancreas) in the database with 224 
full treatment planning data, patient reported outcomes, clinician assessments on-treatment 225 
and in follow-up, disease response as well as diagnosis, and lab data interfaced from clinical 226 
systems.  Data are currently included from Johns Hopkins, the University of Washington, the 227 
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 The rapid access to the treatment data enables data science models to be explored (12). 229 
The Oncospace group is now building predictive models for specific clinical decisions using 230 
classification and regression tree models for weight loss and xerostomia prediction in head and 231 
neck cancer and surgical candidacy in pancreatic cancer. The challenge in clinical prediction is to 232 
focus on the decision to be made and what information truly informs it. For weight loss, the 233 
decision is around the appropriate symptom management for improved nutritional support 234 
such as feeding tube placement. In other cases, modifications to the treatment plan may 235 
reduce risks if it does not compromise on target coverage. Additionally, the impact of the 236 
spatially distributed radiation dose beyond DVHs to better understand how the patterns of 237 
dose may impact the treatment related toxicities could be explored (13). The continued data 238 
growth will allow continuous learning to fulfill the concept of a learning health system in the 239 
future (14). 240 
 241 
University of Pennsylvania 242 
The Penn Medicine Oncology Research and Quality Improvement Datamart (ORQID) 243 
aggregates data from multiple source information systems, including Penn’s enterprise EHR, 244 
ROIS, TPS, Cancer Registry, and Center for Personalized Diagnostics. ORQID focuses on 245 
organizing cancer patients’ demographics, vital status, disease stage and prognostic indicators, 246 
genomic variants, details of systemic therapy and external-beam radiotherapy, and physician-247 
reported toxicities. 248 
Outcomes have been among the most challenging data elements to capture. Penn 249 
implemented structured, site-specific templates for documenting physician-reported toxicities 250 
within the EHR in 2011. The templates are based on the CTCAE grading system, and clinical 251 
teams selected the toxicities of focus for each disease site. To maximize opportunities for data 252 
capture by providers at all levels, only clinically symptomatic toxicities (e.g. pain) not requiring 253 
diagnostic interpretation (e.g. radiation pneumonitis) were included. Nurses have embraced 254 
the effort and capture rates have been as high as 95% for on-treatment visits, which they 255 
routinely staff. Physician adoption has been more challenging, and for follow-up visits (which 256 
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amassed over 2 million toxicity observations on over 28,000 unique patients in the datamart. 258 
Efforts are currently underway to implement widespread patient-reported outcome collection 259 
as routine standard of care to help augment and complement the physician-reported toxicities. 260 
For other outcomes, progression is tracked via the institutional cancer registry, which 261 
only documents the timing and nature of the first progression event after initial treatment. 262 
Deaths are identified from the EHR, cancer registry, and social security death masterfile, but 263 
remain a challenge, with many deaths not documented or without accurate dates. 264 
 265 
US Veterans Health Administration (VHA) Radiation Oncology Practice Assessment 266 
The National Radiation Oncology Program (NROP) office of VHA, with an oversight of 40 267 
radiation therapy treatment centers treating over 15,000 patients annually has launched a pilot 268 
program initiative in which patient-specific radiotherapy data is collected for quality assurance 269 
assessment and comparative analysis of many treatment modalities and other factors at their 270 
centers (15). The NROP office collaborated with the American Society of Radiation Oncology 271 
(ASTRO) disease site expert committees to define clinical measures. These clinical measures are 272 
based on established clinical guidelines, patterns of care assessment done by the American 273 
College of Radiology’s Quality Research in Radiation Oncology program (16), and expert 274 
consensus opinions. These measures have formed the basis for assessing the quality of 275 
treatments and practice variations and identification of the care gaps in the VHA. Although 276 
dosimetry data was automatically abstracted from treatment planning systems (TPS), clinical 277 
data had to be manually abstracted from the electronic health records (EHR) for the pilot 278 
project. 279 
The NROP office has embarked on a project to automatically extract all data for ROPA 280 
from heterogeneous data sources that include EHR, TPS and Treatment Management Systems 281 
(TMS) for clinical practice assessment, outcomes, and prospective decision support analytics. 282 
An integrated data curation, storage and analytics portal, titled as HINGE (Health Information 283 
Gateway and Exchange), was built that can extract and aggregate data from TPS and TMS, 284 
physician clinical notes and DICOM-RT files. HINGE integrates data from these disparate sources 285 
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database is based on well-defined quality measures defined by radiation oncology disease site 287 
experts. HINGE has (i) tools to aggregate data from physician note templates (ii) a built-in 288 
DICOM-RT parser to extract DVH based dose constraints, (iii) a natural language processing 289 
(NLP) module to extract relevant physician assessments from the clinician notes, and (iii) a 290 
decision-support and genomics module to provide supplementary insight to treatment 291 
predictions, treatment outcomes and research hypotheses. The HINGE application would reside 292 
at each VHA radiation oncology treatment site and transmit information to a centralized 293 
database server thus making big data analytics possible. HINGE is capable of seamlessly 294 
connecting to local IT/medical infrastructure via network and performs data extraction and 295 
aggregation. The built-in modules (TMS extraction, DICOM parser, NLP) extract defined clinical 296 
data and are easily extendable. The modules of decision-support and genomics provide 297 
preliminary insights into a patient's treatment and health profile. Automatic data abstraction 298 
with HINGE will enable real time assessment of clinical practices and determine care gaps.  299 
 300 
Mayo Clinic Florida 301 
 The Mayo Clinic Florida Department of Radiation Oncology has leveraged Mayo Clinic’s 302 
unique cost warehouse to aggregate data on the cost of radiation therapy and other associated 303 
healthcare costs in the first two years after radiotherapy on approximately 3,000 patients over 304 
a five year period incurred.  The Mayo cost data warehouse is a unique resources consisting of 305 
linked EMR data and administrative data from Mayo Clinic’s hospital and clinics in Florida, 306 
Minnesota, and Wisconsin (17). These costs were linked to other sources of institutional data, 307 
such as departmental treatment records captured through its radiation oncology information 308 
system, demographic, tumor specific, and outcomes data obtained through Mayo’s tumor 309 
registry, adverse events recorded in the EMR, and other disease specific registries containing 310 
non-oncological diagnosis data, such as psychiatric comorbidities.  Waddle et al have used this 311 
cost warehouse to demonstrate that patients with co-existing psychiatric morbidities utilize the 312 
emergency department and inpatient hospitalization at rates greater than patients without 313 
psychiatric co-morbidities at 6 months and two years after radiotherapy. (18)  It should be 314 
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 316 
The Radiogenomics Consortium (RGC) 317 
The hypothesis that genetic/genomic alterations may function as surrogate biomarkers 318 
of disease response or normal tissue toxicity represents the basis of the field of radiogenomics 319 
(19). A principal goal of research in the field of radiogenomics is to identify the genomic 320 
markers associated with the development of adverse outcomes resulting from cancer 321 
radiotherapy.  However, in order to accomplish this goal and definitively discover and validate 322 
the critical genomic markers, access to the radiotherapy treatment information and long-term 323 
longitudinal follow-up data reporting details as to adverse outcomes must be obtained for large 324 
numbers of patients. In order to enable the creation of large cohorts of patients who received 325 
radiotherapy, the Radiogenomics Consortium (RGC) was created in 2009, which is a cancer 326 
epidemiology consortium through the Epidemiology and Genomics Research Program of the 327 
NCI of the NIH (20). The RGC now has 225 investigators at 132 institutions in 31 countries. 328 
Although the RGC has successfully assembled large cohorts to perform adequately-powered 329 
studies, data harmonization remains a problem when multiple cohorts involve patients treated 330 
with a variety of radiotherapy techniques and evaluated using multiple grading systems. 331 
Nevertheless, a number of large studies have been accomplished in which substantial amounts 332 
of radiotherapy data have been gathered for studies that typically comprise over a thousand 333 
patients. 334 
Four large studies involving the use of Big Data are currently in progress whose main 335 
goal is to discover new SNPs and validate previously identified genetic biomarkers predictive of 336 
susceptibility for the development of adverse effects resulting from radiotherapy. The first 337 
project involves roughly 6,000 men treated for prostate cancer, which encompasses multiple 338 
cohorts created by RGC investigators. DNA samples from all of these men have been genotyped 339 
and detailed clinical data are available with a minimum of two-years of follow-up.  340 
 The second large multi-center study developed by RGC members is REQUITE 341 
(Validation of predictive models and biomarkers of radiotherapy toxicity to reduce side-effects 342 
and improve quality-of-life in cancer survivors)(21). REQUITE addresses the challenge of data 343 
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outcome measures and confounding variables used in multiple cohorts. This study does not 345 
stipulate the radiotherapy protocols to be used but involves standardized case report forms 346 
across centers and countries to ensure data in identical categories are collected. A key aspect of 347 
REQUITE is the centralized database that includes pre-treatment DICOM and DVH files.  348 
 A third study involves three large cohorts comprising roughly 4,500 breast cancer 349 
patients treated with radiotherapy for which blood samples and detailed clinical information 350 
are available. These samples and data are available from three large groups of patients: (1) 351 
1,500 patients treated under a series of breast cancer clinical protocols performed at New York 352 
University School of Medicine (22-25); (2) ~2,000 breast cancer patients enrolled though the 353 
REQUITE study and (3) ~1,000 women who receive breast cancer treatment through 354 
participation in RTOG 1005 (26). 355 
 The fourth effort being made is to create a biorepository with linked clinical data for 356 
patients treated with charged particle therapy (CPT). With the increasing use of CPT, there is a 357 
need to establish cohorts for patients treated with these advanced technology forms of 358 
radiotherapy. In recognition that the formation of patient cohorts treated with CPT for 359 
radiogenomic studies is a high priority, efforts are underway to establish collaborations 360 
involving institutions treating cancer patients with protons and/or carbon ions as well as 361 
consortia, including the Proton Collaborative Group, the Particle Therapy Cooperative Group 362 
and the Pediatric Proton Consortium Registry.  363 
  364 
State of the data  365 
 As noted by the varied workflows highlighted in the use cases, hospital-wide and 366 
radiation oncology-specific EHR systems are not often designed to facilitate collection of key 367 
data elements for subsequent extraction and use. Typically, when a patient is referred to 368 
radiation oncology, the diagnosis for that patient has been entered to the hospital EHR system. 369 
Most radiation oncology-specific EHRs can link to the hospital EHR via HL7 FHIR (27) to sync the 370 
diagnosis information. However, linking the specific diagnosis relevant to a given treatment 371 
plan is often a manual process requiring physician input. In addition, there is generally not a 372 
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sites to the original diagnosis, which are in general of interest for outcome analyses. Thus, 374 
curation of the diagnosis and staging information that comes into radiation oncology can be 375 
cumbersome. Apart from simple diagnosis information, data elements from pathology, 376 
radiology, surgery, internal medicine and medical oncology that may be relevant for radiation 377 
oncology outcomes are seldom entered in discrete fields or even templated free-text formats, 378 
and are, therefore, often inaccessible for automatic extraction and use. 379 
 As the patient goes through treatment, physicians typically see the patient weekly for 380 
on treatment visits. However, the documentation of these visits, including routine toxicity 381 
assessments relies on each individual institution creating their own clinical practice, datasheets 382 
and custom tools for reporting. While many institutions are beginning to recognize the 383 
importance of standardized toxicity assessments and PROs and are putting mechanisms in place 384 
to track this data, there is still inconsistency, which can lead to missing data.  Further, once 385 
institutions have these tools in place, it can be challenging to share personalized templates 386 
across the varying platforms and clinical workflows that exist at different institutions.  Adding 387 
this to the lack of standardized key data elements and time points to track for different 388 
treatment sites, multi-institutional datasets are rarely comprehensive.   389 
 While some existing standards can be leveraged, it is important to evaluate if these 390 
standards take into account the needs of all stakeholders and if not, determine if new 391 
standards or perhaps simply minor amendments can be suggested to minimize the need to 392 
start at the ground up. One must recognize that efforts to standardize common data elements 393 
is a complex and time-consuming endeavor, but one that is ultimately worthwhile. An excellent 394 
published discussion and proposed set of standard patient-reported outcomes within oncology 395 
shows the complexity of these issues (28). 396 
Once collected, Big Data will perform a crucial role by providing accurate outcome data 397 
in order to build clinical decision support systems (CDSS) (29).  Conversely, decision models 398 
themselves can be used to guide the selection of data elements to include.  In a recent work, 399 
for example, a decision cost-model in the form of an influence diagram was constructed to 400 
model the choice between photons and protons for the treatment of locally advanced non-401 
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possible to determine the ROC characteristics of a biomarker for radiosensitivity that a 403 
physician would need in order to select patients for proton radiotherapy when their total 404 
expected cost for protons is below that of photons.  As this cost-model example illustrates, 405 
models can guide data farming efforts by establishing outcomes that are important for clinical 406 
decision making, and by placing requirements on how accurately these outcomes need to be 407 
known.  In this case, the required sensitivity and specificity were established for a novel test for 408 
radiosensitivity for the decision to lower treatment costs.  This use of models may be especially 409 
important when resources (e.g. cost of human labor) for populating databases are limited, 410 
allowing efforts to be directed towards collecting the data that is most likely to lead to 411 
improved clinical decision making.   412 
This in turn highlights an important issue in constructing data standards for capturing 413 
outcome data, namely, the standards need to be easily expandable.  As big data results are 414 
applied in the clinic, used for clinical decision support, or new interactions are discovered 415 
within the data, these efforts will inevitably – and rapidly – call for the collection of different 416 
types of data.  Adaptability is emerging as a feature of data and communication standards 417 
throughout healthcare, as recognition grows that developing a standard which attempts to 418 
include everything will fail to do so, and in the process will become unwieldly.  HL7 FHIR, for 419 
example, is a communication standard which follows an 80/20 directive, whereby 80% of the 420 
elements which are implemented are included in the specification itself (31).  These core 421 
elements are referred to as resources, and the remaining elements, called profiles, are 422 
definable by individual institutions or groups in order to alter or add properties to resources.  423 
Single institution databases can attempt to cover a greater proportion than 80%, although the 424 
principle remains.  By embedding adaptability within a database initially intended to capture, 425 
for example, only traditional treatment planning data, the database may later be populated 426 
with patient reported outcomes, “omics” data, or patient preferences in the form of utilities, 427 
rendering it useful in significantly more applications. 428 
 429 
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 In order for the promise of big data to be realized in more than just individual radiation 431 
oncology departments or networks of systems, standardized key data element lists and input 432 
schemas are required. For example, the connection of diagnosis information to treatment 433 
courses should be automated within vended systems and reviewed for quality on an ongoing 434 
basis as part of a routine workflow, such as chart rounds. In addition, the relevant staging, 435 
pathology, and histology information should be automatically extracted from the EHRs into 436 
appropriate fields within the radiation oncology information system. Free-text searches or 437 
simple natural language processing will be necessary for scanned outside hospital reports and 438 
for other information not entered in discrete fields for easy extraction, particularly for 439 
information not generated in radiation oncology and thus beyond our immediate control. 440 
 Collection of standardized key data elements related to toxicity, disease status, and 441 
patient reported outcomes requires the definition of standards, as discussed above. However, 442 
even with standard elements and data entry tools, there must be a culture shift in the radiation 443 
oncology community to recognize the importance of comprehensive entry of the data as part of 444 
the standard care for each patient. It is our responsibility to the field and future patients to 445 
make collection of key data elements related to outcomes a priority.   446 
 447 
Access and Extraction  448 
 Accessibility and extraction of the clinical data entered by the physician and patients, in 449 
the case of patient-reported outcomes, is essential. The data storage infrastructure must 450 
provide a mechanism for end users to extract the key data elements and aggregate the data 451 
with other related data, such as dosimetric information. The system should be designed with 452 
accessible application programming interfaces enabling user data extraction in the most 453 
suitable and meaningful way. However, data extraction should not be performed on a project-454 
by-project basis. Rather, institutional information technology groups, especially those housed in 455 
radiation oncology, should make it a priority and be proactive in supporting the construction of 456 
big data analytics resource systems (BDARS).  This may require a partnership between radiation 457 
oncology users and the IT managers so that domain knowledge can be shared and the BDARS 458 
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development and use of a radiation oncology-specific ontology will be a key development in 460 
ensuring that individual BDARS can be combined into true sets of big data.    461 
 462 
Specific Recommendations for Standardizations  463 
 While there is clear work ahead in the community to reach a point where standard key 464 
data elements are recorded routinely for all patients in radiation oncology, there are first steps 465 
that can be taken. Summarized in Table 2 are example standard key data elements that could 466 
be collected and thus should begin to be supported by vended systems.  Note that many such 467 
elements would be collected at various timepoints including baseline, during treatment, end of 468 
treatment, and at follow-up.  Therefore, properly capturing dates and being consistent with 469 








While Table 1 serves as a starting point for standardization of requested data elements, 478 
collection of the data requires:  479 
 480 
1. Creation of a standardized workflow that enables collection of proper data, at the right time 481 
for the right patient. 482 
2. Initiation of a working group to develop standards for classifying recurrence in radiation 483 
oncology that includes spatial and dose information. 484 
 485 
Recommendations for Next Steps Needed to Improve Data Availability 486 
 The current climate is such that “big data” is becoming a known term and fills one with 487 
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data mining, as if the data is sitting waiting to be taken and analyzed. However, it is clear that 489 
the data must be created and structured in a way to make it possible to harvest and answer 490 
important and relevant clinical questions. As more providers buy into the need to standardize 491 
for the sake of quality and process improvement, they will become more committed to 492 
inputting essential common data elements related to outcomes. Vendors must also allow the 493 
data to be accessed in a variety of ways, maintaining HIPAA compliance but no longer being a 494 
major barrier to quality assurance. Improved automation in both capturing and accessing data 495 
within vended systems is recommended to improve efficiency and accuracy in capturing 496 
outcomes data. Engagement with all stakeholders, including physicians, legislators, patients and 497 
patient advocates is essential to design modern approaches to handling protected health 498 
information and drafting policies and legislation regarding how health care data can be used in 499 
a safe way so as to maximize healthcare value and efficiency while maintaining security.   500 
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Table 2.  Example Key Data Elements for Radiation Oncology 
 Key Data Element Category Diagnosis = 
breast cancer 
Diagnosis = lung 
cancer 
Diagnosis = bone 
met 






TNM staging TNM staging TNM staging N/A 
Performance Status KPS KPS KPS 
Toxicity Data Elements  
with CTCAE grade 
Dermatitis Dermatitis Dermatitis 
  Pain Pain Pain 
    Esophagitis   
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Recurrence Data Elements Local recurrence Local recurrence Local recurrence 











Generic Data Element 
{name=___, description=___} 
Custom Custom Custom 
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